Views & Analysis Merck KGaA's bold new approach to cancer immunotherapy Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.